Charles River Associates (CRA) Enhances Life Sciences Practice
Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced Tony Bower has joined as a Vice President in its Life Sciences practice. Dr. Bower will be based in CRA’s San Francisco office.
“We’re pleased to welcome Tony,” said CRA’s President and Chief Executive Officer Paul Maleh. “His presence will greatly enhance the strong team of life sciences experts we have on the West Coast.”
Life Sciences Practice Leader Greg Bell said, “Tony is a proven leader in helping companies navigate market access challenges. His background will complement the services that CRA provides to our clients in the healthcare and technology spaces.”
Dr. Bower has 25 years of market access experience as a consultant to, and executive in, the biotechnology industry in the United States and abroad. His expertise encompasses pricing strategy, market access, outcomes research and, generally, scaling and improving the effectiveness of growing pharmaceutical and biotech companies. Dr. Bower has worked on more than 35 products in the United States and globally in rare disease, large retail markets, and oncology.
In addition to establishing his own consulting firm, Dr. Bower held leadership roles in large commercial entities such as Amgen, and small to midsize biotech companies such as Synageva Biopharma. At Synageva, he was brought in as Vice President to build out a new organization and strategy for pricing, reimbursement, and health economics. At Amgen, while based in Europe, he led pricing and contract strategy development and operational execution for the $3 billion business and established annual pricing guidance by country for dozens of products.
Dr. Bower published peer-reviewed articles and monographs during his tenure as Senior Economist at RAND Corporation and also published outcomes research while at Amgen, ALZA, and Synageva. He holds a PhD degree in Economics from Stanford University.
About CRA's Life Sciences Practice
The CRA Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients’ toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.
About Charles River Associates (CRA)
Charles River Associates is a leading global consulting firm specializing in economic, financial and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Twitter, and Facebook.
SAFE HARBOR STATEMENT
Statements in this press release concerning the addition of Tony Bower, the Life Sciences practice, future business Tony Bower may generate for CRA and statements using the terms “enhance”, “expand” or similar expressions are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by CRA include, among others, the failure to generate engagements for us; dependence on the growth of our litigation or strategy consulting practice, the potential loss of clients; the demand environment; global economic conditions; foreign exchange rate fluctuations; and intense competition, as well as other potential factors that could affect our financial results are included in our periodic filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” We cannot guarantee any future results, levels of activity, performance, or achievement. We undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.
CRA International Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de